Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.

IF 6.4 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2024-11-16 DOI:10.1038/s41416-024-02874-6

Robert D Morgan, Xin Wang, Bethany M Barnes, Laura Spurgeon, Aurore Carrot, Daniel Netto, Jurjees Hasan, Claire Mitchell, Zena Salih, Sudha Desai, Joseph Shaw, Brett Winter-Roach, Helene Schlecht, George J Burghel, Andrew R Clamp, Richard J Edmondson, Benoit You, D Gareth R Evans, Gordon C Jayson, Stephen S Taylor

{"title":"Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.","authors":"Robert D Morgan, Xin Wang, Bethany M Barnes, Laura Spurgeon, Aurore Carrot, Daniel Netto, Jurjees Hasan, Claire Mitchell, Zena Salih, Sudha Desai, Joseph Shaw, Brett Winter-Roach, Helene Schlecht, George J Burghel, Andrew R Clamp, Richard J Edmondson, Benoit You, D Gareth R Evans, Gordon C Jayson, Stephen S Taylor","doi":"10.1038/s41416-024-02874-6","DOIUrl":null,"url":null,"abstract":"Background: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.Methods: A retrospective study of patients with newly diagnosed FIGO stage IIIC/IV HGSOC prescribed NACT and tested for gBRCA1/2 pathogenic variants (PVs) between September 2017 and December 2022 at The Christie Hospital. The Cox proportional hazards model evaluated the association between survival and key clinical factors. The chi-square test assessed the association between CRS3 (no/minimal residual tumour) and gBRCA1/2 status.Results: Of 586 eligible patients, 393 underwent DPS and had a CRS reported. Independent prognostic factors by multivariable analysis were gBRCA1/2 status (PV versus wild type [WT]), CRS (3 versus 1 + 2), surgical outcome (complete versus optimal/suboptimal) and first-line poly (ADP-ribose) polymerase-1/2 inhibitor maintenance therapy (yes versus no) (all P < 0.05). There was a non-significant trend for tumours with a gBRCA2 PV having CRS3 versus WT (odds ratio [OR] = 2.13, 95% confidence intervals [CI] 0.95-4.91; P = 0.0647). By contrast, tumours with a gBRCA1 PV were significantly less likely to have CRS3 than WT (OR = 0.35, 95%CI 0.14-0.91; P = 0.0291).Conclusions: Germline BRCA1/2 genotype was not clearly associated with superior omental CRS. Further research is required to understand how HGSOC biology defines CRS.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-024-02874-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response score (CRS). We investigated whether germline BRCA1/2 (gBRCA1/2) genotype associated with omental CRS phenotype.

Methods: A retrospective study of patients with newly diagnosed FIGO stage IIIC/IV HGSOC prescribed NACT and tested for gBRCA1/2 pathogenic variants (PVs) between September 2017 and December 2022 at The Christie Hospital. The Cox proportional hazards model evaluated the association between survival and key clinical factors. The chi-square test assessed the association between CRS3 (no/minimal residual tumour) and gBRCA1/2 status.

Results: Of 586 eligible patients, 393 underwent DPS and had a CRS reported. Independent prognostic factors by multivariable analysis were gBRCA1/2 status (PV versus wild type [WT]), CRS (3 versus 1 + 2), surgical outcome (complete versus optimal/suboptimal) and first-line poly (ADP-ribose) polymerase-1/2 inhibitor maintenance therapy (yes versus no) (all P < 0.05). There was a non-significant trend for tumours with a gBRCA2 PV having CRS3 versus WT (odds ratio [OR] = 2.13, 95% confidence intervals [CI] 0.95-4.91; P = 0.0647). By contrast, tumours with a gBRCA1 PV were significantly less likely to have CRS3 than WT (OR = 0.35, 95%CI 0.14-0.91; P = 0.0291).

Conclusions: Germline BRCA1/2 genotype was not clearly associated with superior omental CRS. Further research is required to understand how HGSOC biology defines CRS.

查看原文本刊更多论文

胚系 BRCA1/2 状态与高级别浆液性卵巢癌化疗反应评分。

背景：高分化浆液性卵巢癌（HGSOC）可通过铂类新辅助化疗（NACT）和延迟初次手术（DPS）进行治疗。对新辅助化疗的组织病理学反应可通过伯姆化疗反应评分（CRS）进行评估。我们研究了种系BRCA1/2（gBRCA1/2）基因型是否与网膜CRS表型相关：回顾性研究：2017年9月至2022年12月期间，克里斯蒂医院对新诊断的FIGO IIIC/IV期HGSOC患者进行了NACT处方和gBRCA1/2致病变体（PVs）检测。Cox比例危险模型评估了生存率与主要临床因素之间的关系。卡方检验评估了CRS3（无/极小残留肿瘤）与gBRCA1/2状态之间的关联：在586名符合条件的患者中，393人接受了DPS并报告了CRS。通过多变量分析得出的独立预后因素包括：gBRCA1/2状态（PV与野生型[WT]）、CRS（3与1 + 2）、手术结果（完全与最佳/次佳）和一线多聚（ADP-核糖）聚合酶-1/2抑制剂维持治疗（是与否）（所有P均为0）：种系 BRCA1/2 基因型与网膜 CRS 优越性无明显关联。要了解 HGSOC 生物学如何定义 CRS，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.